C
Cheryl Gillett
Researcher at King's College London
Publications - 146
Citations - 12223
Cheryl Gillett is an academic researcher from King's College London. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 52, co-authored 136 publications receiving 11077 citations. Previous affiliations of Cheryl Gillett include Guy's and St Thomas' NHS Foundation Trust & Guy's Hospital.
Papers
More filters
Journal ArticleDOI
Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: An index of cell proliferation with evidence of deregulated expression in some, neoplasms
Peter A. Hall,David A. Levison,A. L. Woods,C. C.-W. Yu,D. B. Kellock,J. A. Watkins,Diana M. Barnes,Cheryl Gillett,Richard Camplejohn,Robin Dover,N. H. Waseem,David P. Lane +11 more
TL;DR: Data suggest that in normal tissues and lymphoid neoplasms, PCNA immunolocalization can be used as an index of cell proliferation, however, in some forms of neoplasia, including breast and gastric cancer and in vitro cell lines, the simple relation between PCNA expression and cell proliferation is lost.
Journal Article
Amplification and Overexpression of Cyclin D1 in Breast Cancer Detected by Immunohistochemical Staining
Cheryl Gillett,Vera Fantl,Rosalind Smith,C. J. Fisher,Jiri Bartek,Clive Dickson,Diana M Barnes,Gordon Peters +7 more
TL;DR: The results suggest that the frequency of overexpression is much higher than previously concluded from DNA-based analyses and that more than one-third of human breast cancers may contain excessive levels of cyclin D1.
Journal ArticleDOI
FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer
Nicholas C. Turner,Alex Pearson,Rachel Sharpe,Maryou B K Lambros,Felipe C. Geyer,María Ángeles López-García,Rachael Natrajan,Caterina Marchiò,Elizabeth Iorns,Alan Mackay,Cheryl Gillett,Anita Grigoriadis,Andrew Tutt,Jorge S. Reis-Filho,Alan Ashworth +14 more
TL;DR: The data suggest that amplification and overexpression of FGFR1 may be a major contributor to poor prognosis in luminal-type breast cancers, driving anchorage-independent proliferation and endocrine therapy resistance.
Journal ArticleDOI
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: The TNT Trial
Andrew Tutt,Andrew Tutt,Holly Tovey,Maggie C.U. Cheang,Sarah Kernaghan,Lucy Kilburn,Patrycja Gazinska,Julie Owen,Jacinta Abraham,Sophie Barrett,Peter Barrett-Lee,Robert S. Brown,Robert S. Brown,Stephen Chan,Mitchell Dowsett,Mitchell Dowsett,James M. Flanagan,Lisa Fox,Anita Grigoriadis,Alexander Gutin,Catherine Harper-Wynne,Matthew Hatton,Katherine A. Hoadley,Jyoti Parikh,Peter J. Parker,Peter J. Parker,Charles M. Perou,Rebecca Roylance,Vandna Shah,Adam Shaw,Ian E. Smith,Kirsten Timms,Andrew M Wardley,Gregory C. Wilson,Cheryl Gillett,Jerry S. Lanchbury,Alan Ashworth,Nazneen Rahman,Nazneen Rahman,Mark Harries,Paul Ellis,Sarah E Pinder,Judith M Bliss +42 more
TL;DR: The phase 3 TNT Trial in subjects with triple-negative breast cancer supports the superiority of carboplatin over docetaxel in BRCA1/2-mutated tumors and a greater response to taxanes in the nonbasal subtype, and concludes that patients with advanced TNBC benefit from characterization of BRC a/2 mutations, but not BRC1 methylation or Myriad HRD analyses, to inform choices on platinum-based chemotherapy.
Journal ArticleDOI
BRCA1 dysfunction in sporadic basal-like breast cancer.
Nicholas C. Turner,Jorge S. Reis-Filho,Jorge S. Reis-Filho,AM Russell,R J Springall,K Ryder,Dawn Steele,Kay Savage,Cheryl Gillett,Fernando Schmitt,Alan Ashworth,Andrew Tutt,Andrew Tutt +12 more
TL;DR: The high prevalence of BRCA1 dysfunction identified in this study could be exploited in the development of novel approaches to targeted treatment of basal-like breast cancer.